Search
BeiGene's BCL2 Inhibitor Zotiraciclib Receives Approval for Marketing Authorization Application in China
2025-04-29 /
Read about 0 minute
Author：小编
BeiGene's application for the marketing authorization of its BCL2 inhibitor, zotiraciclib tablets, has been accepted by the Center for Drug Evaluation (CDE). The drug is proposed to enter the priority review process, with the aim of treating adult patients who have previously received treatment for chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). CLL/SLL is a prevalent hematological malignancy, and zotiraciclib tablets, as a new generation of BCL2 inhibitors, effectively rejuvenate the apoptosis pathway of tumor cells. Given the unfavorable prognosis faced by CLL/SLL patients in China, this drug offers a much-anticipated innovative treatment option.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
